Genomic variation in symptom expression in castrate-resistant prostate cancer
Although multiple factors can influence symptom severity, genetic variation may play a part. The early identification of men likely to develop severe symptoms during the course of their prostate cancer could theoretically enable symptoms to be managed more aggressively from an early stage. These preliminary findings need to be replicated in a larger cohort of men with CRPC.
Authors
- Ristan M. Greer (ORCID: https://orcid.org/0000-0002-1574-4729)
- Karyn Foster (ORCID: https://orcid.org/0000-0002-7525-1547)
- Adam D. Ewing (ORCID: https://orcid.org/0000-0002-4544-994X)
- Petra Vayne-Bossert (ORCID: https://orcid.org/0000-0003-4642-4290)
- Janet Hardy (ORCID: https://orcid.org/0000-0003-1127-9951)
- Phillip D. Good (ORCID: https://orcid.org/0000-0002-8198-0375)
- Niara Oliveira (ORCID: https://orcid.org/0000-0001-7103-2200)
Institutions
- The University of Queensland (AU)
- Mater Misericordiae Hospital (AU)
- Mater Research (AU)
- University Hospital of Geneva (CH)
- St Vincent’s Private Hospital Brisbane (AU)
- Geneva College (US)
Publication Details
- Journal
- BMJ Supportive & Palliative Care
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1136/spcare-2025-005510
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00